CLDX Share Price

Open 3.40 Change Price %
High 3.41 1 Day -0.02 -0.59
Low 3.33 1 Week 0.16 5.00
Close 3.36 1 Month -0.04 -1.18
Volume 765016 1 Year -0.83 -19.81
52 Week High 5.13
52 Week Low 2.85
CLDX Important Levels
Resistance 2 3.43
Resistance 1 3.40
Pivot 3.37
Support 1 3.32
Support 2 3.29
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
SIRI 5.02 -1.76%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
INTC 37.43 1.35%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
IFON 0.63 34.04%
WRES 0.09 28.57%
SMSI 1.13 28.41%
EXAS 30.14 26.64%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
OPHC 2.80 21.21%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
PGRX 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SNCR 13.29 -46.02%
DVOX 0.05 -44.44%
More..

Celldex Therapeutics, Inc. (NASDAQ: CLDX)

CLDX Technical Analysis 3
As on 27th Apr 2017 CLDX Share Price closed @ 3.36 and we RECOMMEND Sell for LONG-TERM with Stoploss of 3.84 & Sell for SHORT-TERM with Stoploss of 3.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
CLDX Target for April
1st Target up-side 4.1
2nd Target up-side 4.44
3rd Target up-side 4.78
1st Target down-side 3.12
2nd Target down-side 2.78
3rd Target down-side 2.44
CLDX Other Details
Segment EQ
Market Capital 363793952.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.celldextherapeutics.com
CLDX Address
CLDX
Perryville III Building
53 Frontage Road
Hampton, NJ 08827
United States
Phone: 908-200-7500
Fax: 908-454-1911
CLDX Latest News
Interactive Technical Analysis Chart Celldex Therapeutics, Inc. ( CLDX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Celldex Therapeutics, Inc.
CLDX Business Profile
Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's drug candidates include CDX-110, CDX-011 and CDX-1127. CDX-110, is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). CDX-1127 is a human monoclonal antibody that targets CD27. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology programs, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system.